2009
MATRIX METALLOPROTEINASE -2 GENE VARIABILITY IN PSORIASIS
VAŠKŮ, Vladimír; Julie BIENERTOVÁ VAŠKŮ; Veronika SLONKOVÁ and Anna VAŠKŮBasic information
Original name
MATRIX METALLOPROTEINASE -2 GENE VARIABILITY IN PSORIASIS
Name in Czech
Variabilita v promotoru genu pro matrixmetaloproteinázu 2 u psoriázy
Authors
Edition
2009. vyd. Bukurešť, 6th EADV Spring Symposium on Psoriasis, p. 303-303, 1 pp. 2009
Publisher
EADV
Other information
Language
English
Type of outcome
Proceedings paper
Field of Study
30216 Dermatology and venereal diseases
Country of publisher
Romania
Confidentiality degree
is not subject to a state or trade secret
Marked to be transferred to RIV
No
Organization unit
Faculty of Medicine
Keywords (in Czech)
psoriáza; matrix metaloproteináza 2, polymorfismus, komorbidita
Keywords in English
psoriasis; matrix metalloproteinase 2; polymorphism; comorbidity
Tags
International impact, Reviewed
Changed: 4/5/2009 16:13, prof. MUDr. Julie Vašků, Ph.D.
In the original language
The expression of matrix metalloproteinase-2 was observed to be significantly up regulated in psoriasis. The aim of the study is to associate a DNA polymorphic genotype in MMP-2 promoter gene with psoriasis and/or with psoriasis phenotypes. A total of 386 Czech psoriatic patients were compared to 196 controls of similar age and sex distribution, without personal or family history of chronic skin diseases. In all 580 Czech persons, four MMP-2 promoter polymorphisms (-1575G/A, -1306C/T, -790T/G and -735C/T) were detected by PCR methods. A significant association of GG genotype of -790 MMP-2 polymorphism with psoriasis was observed (Pcorr=0.04). Although no differences in the associated GG(-1575)CC(-1306)TT(-790) MMP-2 promoter genotype frequency between psoriasis patients and controls had been found, the genotype was observed to be highly significantly lower in patients with family history of psoriasis (close as well as distant), family history of diabetes and personal history of allergy (odds ration for GGCCTT in the group is 0.11, 95% confidential interval 0.02-0.50, Pcorr= 0.01). The GGCCTT MMP-2 promoter genotype was observed to be less frequent in patients with all three positive characteristics compared to psoriatic patients without them (odds ratio=0.15, 95% CI = 0.03-0.72 for psoriatic patients with family history of psoriasis and diabetes and with allergy P=0.007, Pcorr= 0.04;). MMP-2 located at psoriasis susceptibility region on 16q (psoriasis susceptibility 8, PSORS8) can be considered a gene-modulator of psoriasis. In the future, similar genetic characteristics could contribute to data assembly of genetic predisposition to psoriasis and could lead to therapy improvement based on time-proved individual pharmacogenetic aspects detected in psoriasis patients.
In Czech
V rámci předkládané studie byly zkoumány možné asociace mezi definovanými variantami v promotoru genu pro matrixmetaloproteinázu 2 a výskytem psoriázy a přidružených onemocnění.
Links
| MSM 141100002, plan (intention) |
|